Repurposing of aging‐preventive pharmaceuticals to delay Alzheimer's disease progression.
Further perspectives: Next steps include treating App<sup>NL-F</sup> knock-in mice and human tau mice with the most promising drug candidates. Biochemical and histological analyses, including immunohistochemistry, will be employed to assess reductions in Aβ and tau pathologies, neuroinflammation, and synaptic alterations. This work explores the potential of repurposing aging-preventive drugs for the prevention or delay of Alzheimer's disease, potentially creating a new strategy to target AD.
Authors
- Simone Tambaro (ORCID: https://orcid.org/0000-0001-7000-7556)
- Alan Kavšek (ORCID: https://orcid.org/0009-0006-0310-6654)
- Dorota Religa (ORCID: https://orcid.org/0000-0003-4583-4570)
- Christian G. Riedel (ORCID: https://orcid.org/0000-0002-3689-8022)
- Sara Hägg (ORCID: https://orcid.org/0000-0002-2452-1500)
- Thaís Lopes de Oliveira (ORCID: https://orcid.org/0009-0000-5377-4809)
- Andrea Mosqueda Solís
- Arvid Sjölander
- Chenxi Qin
- Per Nilsson
- Bowen Tang
- Kristina Johnell
Institutions
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_102599
- Primary Topic
- Genetics, Aging, and Longevity in Model Organisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00